Cure, H <br/><br/>
Results of a phase II trial with cystemustine at 90 mg/m(2) as a first- or second-line treatment in advanced malignant melanoma: a trial of the EORTC Clinical Studies Group.  [electronic resource] 

 -  Melanoma research  Dec 1999 
 - 607-10 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Clinical Trial, Phase II; Journal Article 
<br/><br/><label>ISSN: </label>0960-8931 
<br/><br/><label>Standard No.: </label>10.1097/00008390-199912000-00011  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antineoplastic Agents--administration & dosage<br/>Combined Modality Therapy<br/>Dacarbazine--therapeutic use<br/>Female<br/>Humans<br/>Immunotherapy<br/>Male<br/>Melanoma--drug therapy<br/>Middle Aged<br/>Neoplasm Staging<br/>Nitrosourea Compounds--administration & dosage<br/>Treatment Outcome